Putative role of ischemic postconditioning in a rat model of limb ischemia and reperfusion: involvement of hypoxia-inducible factor-1α expression

Tekijä Wang, T., Zhou, Y.T., Chen, X.N., Zhu, A.X.
Julkaistu 2014

Cloning and characterization of p97MAPK, a novel human homolog of rat ERK-3.

Tekijä Zhu, A X, Zhao, Y, Moller, D E, Flier, J S
Julkaistu 1994

Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells

Tekijä Feng, M., Jin, J. Q., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Rafi, S., Zhu, A. X., Feng, Y.-X., Zhu, D.
Julkaisussa Sci Adv (2019)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

Tekijä Michaelson, M D, Zhu, A X, Ryan, D P, McDermott, D F, Shapiro, G I, Tye, L, Chen, I, Stephenson, P, Patyna, S, Ruiz-Garcia, A, Schwarzberg, A B
Julkaistu 2013

Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer

Tekijä Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Earle, C. C., Kulke, M. H., Meyerhardt, J. A., Blaszkowsky, L. S., Zhu, A. X., Fidias, P., Vincitore, M. M., Mayer, R. J., Fuchs, C. S.
Julkaistu 2009

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

Tekijä Chan, J. A., Blaszkowsky, L. S., Enzinger, P. C., Ryan, D. P., Abrams, T. A., Zhu, A. X., Temel, J. S., Schrag, D., Bhargava, P., Meyerhardt, J. A., Wolpin, B. M., Fidias, P., Zheng, H., Florio, S., Regan, E., Fuchs, C. S.
Julkaistu 2011

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

Tekijä Blaszkowsky, L. S., Ryan, D. P., Szymonifka, J., Borger, D. R., Zhu, A. X., Clark, J. W., Kwak, E. L., Mamon, H. J., Allen, J. N., Vasudev, E., Shellito, P. C., Cusack, J. C., Berger, D. L., Hong, T. S.
Julkaisussa Ann Oncol (2014)

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

Tekijä Arnold, D, Fuchs, C S, Tabernero, J, Ohtsu, A, Zhu, A X, Garon, E B, Mackey, J R, Paz-Ares, L, Baron, A D, Okusaka, T, Yoshino, T, Yoon, H H, Das, M, Ferry, D, Zhang, Y, Lin, Y, Binder, P, Sashegyi, A, Chau, I
Julkaisussa Ann Oncol (2017)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

Tekijä Hezel, A F, Noel, M S, Allen, J N, Abrams, T A, Yurgelun, M, Faris, J E, Goyal, L, Clark, J W, Blaszkowsky, L S, Murphy, J E, Zheng, H, Khorana, A A, Connolly, G C, Hyrien, O, Baran, A, Herr, M, Ng, K, Sheehan, S, Harris, D J, Regan, E, Borger, D R, Iafrate, A J, Fuchs, C, Ryan, D P, Zhu, A X
Julkaistu 2014